Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up.

ABSTRACT:

Aims

Clinical trials have demonstrated the safety and efficacy of the Micra leadless VVI pacemaker; however, longer-term outcomes in a large, real-world population with a contemporaneous comparison to transvenous VVI pacemakers have not been examined. We compared reinterventions, chronic complications, and all-cause mortality at 2 years between leadless VVI and transvenous VVI implanted patients.

Methods and results

The Micra Coverage with Evidence Development study is a continuously enrolling, observational, cohort study of leadless VVI pacemakers in the US Medicare fee-for-service population. Patients implanted with a leadless VVI pacemaker between March 9, 2017, and December 31, 2018, were identified using Medicare claims data linked to manufacturer device registration da

SUBMITTER: El-Chami MF 

PROVIDER: S-EPMC8934700 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature